Fluvastatin inhibits proliferation that is driven by glycosylated transmembrane receptors. Inhibition of growth was assessed after a 48-hour incubation period using the MTT assay in cell lines driven by either: (A) activated FLT3 including FLT3/ITD (MV4-11, Molm-14 cells), FLT3 (SEMK2 cells), or a D835H kinase domain mutant (HB1119 cells); (B) the nonglycosylated oncogenic intracellular kinases BCR-ABL (K562 cells) or Fes kinase (U937 cells); or (C) other glycosylated transmembrane receptors, such as insulin (HL60 cells), c-Kit (MO7E cells), or mutant c-Kit (Kasumi cells). (D) The effect of fluvastatin was assessed on proliferation of BaF3 cells expressing either FLT3/ITD or BCR-ABL after treatment for 48 hours by MTT. (E) Primary patient AML samples harboring a FLT3/ITD mutation were treated with the indicated concentrations of fluvastatin for 72 hours and analyzed by MTT assay or Western blotting. Typical results are shown for at least 2 separate experiments.